STOCK TITAN

Takeda (NYSE: TAK) CEO Christophe Weber details Form 3 share and award holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Takeda Pharmaceutical’s President and CEO Christophe Weber has reported his initial ownership position on a Form 3. The filing lists direct holdings of 935,300 Ordinary Shares and 253,433 American Depositary Shares, plus various equity-based awards tied to future vesting dates.

The position includes 96,000 restricted stock units (RSUs) linked to Ordinary Shares, vesting on June 1, 2026 (46,100 shares), June 1, 2027 (32,700 shares) and June 1, 2028 (17,200 shares. It also includes 204,008 RSUs linked to American Depositary Shares, vesting on July 1, 2026 (95,744 shares), July 1, 2027 (72,384 shares) and July 1, 2028 (35,850 shares).

Weber also holds Tax Obligation Awards that are economically equivalent to Ordinary Shares, with underlying amounts of 46,367, 32,966 and 17,296 Ordinary Shares, expiring on June 1, 2026, June 1, 2027 and June 1, 2028. Upon vesting, these Tax Obligation Awards convert into cash payments primarily to cover tax obligations based on the then-current Ordinary Share price.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Weber Christophe Pierre

(Last)(First)(Middle)
2-1-1 NIHONBASHI-HONCHO
CHUO-KU

(Street)
TOKYO103-8668

(City)(State)(Zip)

JAPAN

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares935,300(1)D
American Depositary Shares253,433(2)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Tax Obligation Award06/01/202606/01/2026Ordinary Shares46,367(3)D
Tax Obligation Award06/01/202706/01/2027Ordinary Shares32,966(3)D
Tax Obligation Award06/01/202806/01/2028Ordinary Shares17,296(3)D
Explanation of Responses:
1. Includes 96,000 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (46,100 shares), June 1, 2027 (32,700 shares) and June 1, 2028 (17,200 shares).
2. Includes 204,008 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (95,744 shares), July 1, 2027 (72,384 shares) and July 1, 2028 (35,850 shares).
3. Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
Remarks:
Exhibit 24 Power of Attorney
/s/ Max Heuer, by power of attorney, for Christophe Weber03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Takeda (TAK) CEO Christophe Weber report on this Form 3?

Christophe Weber reports his initial ownership in Takeda, including 935,300 Ordinary Shares and 253,433 American Depositary Shares held directly. The filing also details multiple restricted stock unit awards and Tax Obligation Awards tied to future vesting and expiration dates.

How many restricted stock units on Ordinary Shares does Takeda (TAK) CEO hold?

The CEO holds 96,000 restricted stock units related to Ordinary Shares. These RSUs vest in three tranches: 46,100 shares on June 1, 2026, 32,700 shares on June 1, 2027, and 17,200 shares on June 1, 2028, subject to the plan terms.

What RSUs linked to American Depositary Shares does Takeda (TAK) disclose for its CEO?

The filing shows 204,008 restricted stock units tied to American Depositary Shares. These vest on a schedule of 95,744 shares on July 1, 2026, 72,384 shares on July 1, 2027, and 35,850 shares on July 1, 2028, reflecting multi-year equity compensation.

What are the Tax Obligation Awards reported by Takeda (TAK) CEO Christophe Weber?

Tax Obligation Awards are instruments economically equivalent to one Ordinary Share each, converting into cash payments at vesting. They primarily cover tax obligations using then-current Ordinary Share prices, with underlying amounts of 46,367, 32,966 and 17,296 shares expiring in 2026, 2027 and 2028.

Does this Takeda (TAK) Form 3 show any insider share purchases or sales?

The Form 3 lists ownership and equity awards for the CEO but does not show explicit open-market purchases or sales. Transactions are categorized as holdings, with transaction direction marked as unknown, emphasizing disclosure of existing positions rather than trading activity.

What is the significance of this Takeda (TAK) Form 3 for investors?

This Form 3 establishes a public record of the CEO’s equity stake and incentive structure in Takeda. It outlines direct share ownership, RSUs, and Tax Obligation Awards, helping investors understand how leadership is financially aligned with the company’s Ordinary Shares and ADS performance.
Takeda Pharm

NYSE:TAK

View TAK Stock Overview

TAK Rankings

TAK Latest News

TAK Latest SEC Filings

TAK Stock Data

56.96B
3.16B
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Japan
Tokyo